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CT Screening for lung cancer: is the evidence strong enough? 
 
The prevailing questions at this time in both the public mind and the clinical 
establishment is, do we have sufficient evidence to implement lung cancer CT 
screening? If not, what is outstanding? 
 
This review will address the twelve major areas where we need to assess whether we 
have sufficient evidence to proceed to a recommendation to implement CT screening 
in Europe.  These twelve areas are illustrated in Figure1, with colour codes as to our 
current status in 2015, where green indicates we have sufficient evidence, amber is 
borderline evidence and red requires further evidence. 
 
Background: Lung cancer is an important health problem 
 
Lung cancer is an important cause of ill-health and is the second commonest cancer in 
men and women with around 44,488 new cases diagnosed in the UK each year. The 
number of deaths in 2012 was 35,371, making lung cancer the commonest cause of 
cancer death in the UK for both men and women 
(http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-
cancer-type/lung-cancer). In the European Union (EU-28) 268,000 deaths predicted in 
2012 (http://globocan.iarc.fr/old/FactSheets/cancers/lung-new.asp). The main reasons 
why lung cancer outcomes are so poor are that around 70% of patients first present to 
specialist care with incurable advanced disease and current treatment at this stage has 
very little effect on mortality.  More than one third of all lung cancer patients die 
within three months of diagnosis, despite having multiple visits to their GPs before 
their diagnosis[1]. However, if a patient’s lung cancer is identified at an early stage, 
then the clinical outcome is greatly improved and this is a strong argument for 
seriously considering a national screening programme. 
  
Figure 1 (Insert here) 
 
Reduction in smoking over the last 50 years has made a massive impact on lung 
cancer mortality and smoking cessation interventions are very cost effective. Research 
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is now focused on increasing the effectiveness of smoking cessation and one recent 
approach has been to offer financial incentives. A recent randomised controlled trial 
of four financial-incentive programmes for smoking cessation found that that reward-
based schemes did in fact lead to sustained abstinence, however it would appear that 
the public acceptability of such an approach discourages their adoption [2]. Smoking 
cessation is known to be greater when an individual experiences a significant health 
event, such as myocardial infarction.  CT screening may also represent a significant 
health event and there is some evidence that cessation rates are increased above 
background rates in screening trials [3]. Thus building in smoking cessation, tailored 
to screenees is an important adjunct that is likely to increase cost effectiveness and 
potentially decrease all-cause mortality. 
 
The financial burden of lung cancer is considerable: the estimated cost to the UK 
economy is £2.4 billion each year, £9,071 per patient annually. This is far higher than 
the cost of any other cancer despite survival rates being among the lowest. More 
curative treatment and prevention resulting from integrated screening and smoking 
cessation programmes has the potential to reduce these costs [4]. 
 
1. The evidence for a validated lung cancer screening test in Europe (Green). 
 
The first major breakthrough for lung cancer screening came with the publication of 
the USA National Lung Cancer Screening Trial (NLST) [5], which was the first major 
RCT for lung cancer Low Dose Computed Tomography (LDCT) screening. NLST 
recruited over 53,000 people aged 55–74, with a 30 pack-year smoking history, who 
had smoked within 15 years. These subjects were randomised to LDCT or chest X-
ray, with lung cancer mortality as the outcome. NLST reported a 20% relative 
reduction in lung cancer mortality in the LDCT arm[6]. Furthermore, all-cause 
mortality was reduced by 6.7% in the low-dose CT group compared with the X-ray 
group. This publication provided great optimism for the lung cancer screening 
community, as it provided the first evidence that LDCT screening saved lives.  
 
The recommendations from the first IASLC SSAC workshop represented the only 
truly international view on screening and reported shortly after the publication of the 
NLST trial [7].  The recommendations were: 
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(i)    Optimisation of identification of high-risk individuals;  
(ii)    Development of radiological guidelines;  
(iii)    Development of guidelines for the clinical work-up of indeterminate nodules;  
(iv)    Development of guidelines for pathology reporting;  
(v)   Definition of criteria for surgical and therapeutic interventions of suspicious 
nodules identified through lung cancer CT screening programmes;  
(vi)   Development of recommendations for the integration of smoking cessation 
practices into future national lung cancer CT screening programmes. 
 
It is of note that many of the above areas of concern have been investigated in depth 
following the NLST publication, which included ensuring that future lung cancer 
screening programmes would target the high risk populations who had the greatest 
risk of developing lung cancer, whist minimising the potential for harm, in a cost 
effective manner  [8]. During the intervening years after the NLST publication, five 
clinical and professional groups in the USA have also provided in-depth 
recommendations, which are naturally focused on the USA clinical practice. All of 
these professional groups supported the implementation of CT screening, with 
varying details on the definition of risk groups and the screening methodology. 
However, in 2014, the US Preventive Services Task Force (USPSTF) recommended 
implementation of LDCT screening. The USPSTF commissioned an independent 
analysis of the evidence, which proposed that lung cancer screening should be offered 
to individuals of comparable risk to NLST, but with an extension of the upper the age 
limit to 80 years [9]. The USPSTF recommended that screening should be 
discontinued once a person has not smoked for 15 years or develops a health problem 
that substantially limits life expectancy or the ability or willingness to have curative 
lung surgery. Recently, Medicare, has agreed to cover the costs of screening but they 
did stipulate a number of stringent requirements for inclusion.  
 
2 Participation –Recruitment of the hard to reach (Red) 
 
Added to the issues identified by the international workshop above is that of 
participation in CT screening. The participation rate in breast cancer screening 
programmes is around 70% and for colorectal around 60%. Lung cancer incidence is 
progressively greater with lower socioeconomic status. The lower socioeconomic 
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groups are often hard to engage in healthcare interventions and therefore it is 
important that ways to maximize participation rates are explored. One programme, 
underway in the UK is the Accelerate, Coordinate and Evaluate initiative, funded by 
Cancer Research UK and Macmillan.  This is looking at novel ways to recruit people, 
for example by using mobile CT scanners.  (http://www.cancerresearchuk.org/health-­‐‑professional/early-­‐‑diagnosis-­‐‑activities/ace-­‐‑programme/ace-­‐‑programme-­‐‑projects#ACE_projects1) 
 
NLST provides compelling evidence that CT screening should start as soon as 
possible but there are concerns about how it should be implemented and whether it 
will be cost effective. There are a number of European trials, the largest of which is 
the Dutch-Belgian NELSON trial, which is due to report on mortality within the next 
year. Thus, when pooled with results from other European trials including the pilot 
UK Lung cancer screening trial (UKLS) will be able to answer most of the remaining 
questions. Already these trials have provided important information about optimal 
radiology, nodule management, screen interval and estimated cost-effectiveness. 
Thus, European health care services may be in a position to make a final decision on 
implementing lung cancer screening within the next few years.  
 
It is now internationally acknowledged that if lung cancer screening is not 
implemented in centres of excellence, it is highly unlikely that we will still see the 
same mortality advantage and there is a possibility that there will be a higher 
morbidity associated with CT screening programmes.  
 
2. Evidence to Target high risk populations – using risk prediction modelling 
(Green) 
 
One of the major drivers in ensuring that the benefits of implementing lung cancer 
screening outweigh the harms from screening, is to target individuals with a high risk 
of developing the disease. The future implementation of lung cancer screening 
requires the accurate identification of the individuals who will benefit the greatest 
from LDCT screening programmes, thereby ensuring the benefits outweigh the harms 
from screening. The current recommendations from the USPSTF,  which are mainly 
based on the NLST trial, include screening all individuals between the ages of 55 and 
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80 with a smoking history of 30 pack-years or more [10].  In-depth analysis of the 
NLST has shown that there were significant differences in the number of lung cancer 
cases detected based on their underlying risk, regardless of whether the participants 
fitted the NLST entry criteria: 60% of participants at highest risk for lung-cancer 
death accounted for 88% of the prevented deaths, whereas the 20% of participants at 
lowest risk accounted for only 1% of prevented lung-cancer deaths) [11]. Put another 
way,5276 individuals in the lowest risk quintile had to be screened to prevent one 
cancer death and this resulted in the greatest number of false positives. This compares 
with the highest risk quintile where 161 individuals needed to be screened to prevent 
a lung cancer death. These data argue for a reassessment of the lung cancer risk 
criteria.  
 
The PLCO M2012 risk model, was used to evaluate the risk threshold for selecting 
individuals for screening and compared the efficiency with the USPSTF criteria [12]. 
The mortality rates among NLST participants screened with CT were found to be 
consistently lower than the mortality rates in the chest X-ray arm. Furthermore, the 
PLCOM2012 improved the sensitivity and specificity of the selection of individuals for 
lung cancer screening over the UPSTF criteria.  The major limitation of utilising the 
PLCOM2012 risk ≥0.015 threshold for selecting individuals for LDCT screening trials, 
is that the evaluation was not based on a cost-effectiveness model.   To date, the only 
lung cancer risk prediction model, which has been utilised in the recruitment of 
participants into a CT Lung Cancer Screening RCT, is the Liverpool Lung Project 
(LLPv2) risk model in the UKLS [13]. The LLPv1 risk model was based on a case-
control study [14] utilising conditional logistic regression to develop a model, based 
on risk factors significantly associated with lung cancer  (smoking duration, prior 
diagnosis of pneumonia, occupational exposure to asbestos, prior diagnosis of 
malignant tumour and early onset (<60 years) and family history of lung cancer) [14]. 
The multivariable model was combined with age-standardised incident data to 
estimate the absolute risk of developing lung cancer. The LLP risk model was 
evaluated in three independent studies from Europe and North America (22) and 
demonstrated its predicted benefit. The LLPv2 model included all respiratory disease 
and all smokers (cigarette, pipe and cigar) and was used to select high-risk individual 
in the UKLS [15]. UKLS randomised subjects were selected on the basis of their ≥5% 
risk of developing lung cancer in the next five years. Overall, there was a 1·7% 
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prevalence of lung cancer at baseline [16] which is higher than that reported by the 
NLST[17] or NELSON [18, 19] trials. 
 
4. Screen a specific age range 60-75 years (Green) 
 
An in-depth analysis of the UKLS trial data with respect to the LLPv2 risk status, 
clearly indicates that there is a significant increase in the population approached at the 
age of 58. 
 
In the UKLS trial, the positive response rate ranged from 26.6% in the 50-55 age 
group to 35.0% in the 61-65 age group and then dropping to 27.6% in the 71-75 age 
group. Age is a major component of all lung cancer risk models including the LLPv2 
risk model, where only 82 out of 16,273 positive responders (i.e. 0.5%) in the 50-55 
age group were classified as high risk, compared to 2,046 (24.8%) in the 71-75 group. 
The 50-55 age group had the lowest positive response rate and were the least likely 
age group considered of being at high risk of lung cancer. In the UKLS, in the 50-55 
age group, only 29 of 61,168 individuals originally approached (0.05%) were 
recruited to the RCT. In	  UKLS,	  approximately	  95%	  of	  people	  at	  high	  risk	  were	  60	  or	  greater. thus this age should be chosen to start to initiate a screening  programme. 
 
Figure 2  Percentage of UKLS positive responders (n=75,958) with an LLP risk of 
>5% over 5 years, by individual year of age. 
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5.  LDCT is a highly sensitive test for lung cancer (Green) 
 
Modern CT scanners have been shown to have a sensitivity for detecting cancer of 
over 95% but also are able to reduced the effective radiation dose to below 1.6mSv, 
which is roughly the amount of annual background radiation, compared to 8mSv from 
a regular CT of the thorax [8, 20]  
 
6. Identify ‘indeterminate’ nodules (Green) 
 
There is now a large body of literature providing guidance on the detection, 
characterisation and management of indeterminate lung nodules which are frequently 
benign. Management protocols based on interval imaging with volumetric 
measurement have been shown to be effective in correctly identifying malignant 
lesions and minimizing the need for invasive tests. [18] [17].  The preferred method in 
the US is to rely on diameter measurements using manual electronic calipers. 
However this is known to be less accurate and less reproducible that volumetric 
measurements. In Europe the NELSON, UKLS, DLCST, LUSI and MILD studies 
have all used volumetric analysis [21]. Volumetry can more reliably detect growth, 
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defined as a 25% change in volume between the first and the second scan [18] than 
manual diameter measurement, defined in NLST as a 10% increase in diameter  [17]. 
 
The nodule growth definition and care pathway used within in the UKLS trial is 
shown in Figure 1, which had many similarities to the NELSON methodology. In the 
NELSON trial, nodules less than 50 mm3, were classified as negative, greater than 
500mm3 as positive; 50 to 500mm3 as indeterminate [18]. Indeterminate nodules 
underwent a 3-month follow-up LDCT to assess for growth. Volume doubling times 
(VDTs) [22] were then used to distinguish between positive screens (VDT<400 days) 
requiring additional diagnostic procedures, and negative screens 
 
The recent publication from the NELSON trial team has provided further insight into 
the judgement calls based on nodule volume measurements and volume doubling time 
[23]. Recently the British Thoracic Society produced the ‘Magna Carta’ of nodule 
decision guidelines [24], which has a major overlap with the current practices in CT 
screening programmes that advocate utilising CT nodule volumetric based 
measurements in conjunction with volume doubling times.   
 
A risk prediction based approach has been developed to assess indeterminate nodules 
through risk assessment modelling and attempting to ascertain which nodules are at 
the highest risk of being malignant and thus require immediate intervention apart 
from utilising radiological imaging. This was undertaken using two Canadian cohorts, 
which included participants in the Pan-Canadian Early Detection of Lung Cancer 
Study and participants involved in chemoprevention trials at the British Columbia 
Cancer Agency (BCCA). The final outcomes of all nodules of any size that were 
detected on baseline low-dose CT scans were tracked. The rates of cancer in the two 
data sets were 5.5% and 3.7%, respectively. It is of note the predictors of cancer in the 
model included older age, female sex, family history of lung cancer, emphysema, 
larger nodule size, location of the nodule in the upper lobe, part-solid nodule type, 
lower nodule count, and also spiculation. The ROC was found to be 0.90 [25].  
 
The NELSON investigators have undertaken an in depth analysis of lung cancer 
probability, based on nodule diameter, volume and volume doubling time, utilising 
their data on 7,155 individuals. Lung cancer had a low probability in participants with 
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a nodule volume of <100mm3 or < 5mm diameter (0.6%); which was not significantly 
different from individuals with no nodules. Lung cancer in indeterminate nodules 
100-300mm3 or diameter 5-10mm was 2.4%. However, when volume doubling time 
(VDT) was also taken into account, those with a VDT of 600 days or more has a risk 
of 0.8% , VDT of 400-600 days was 4.0% and a VDT of 400 days or less was 9.6% 
[26].  These data provided further evidence that nodules with a diameter of less than 
5mm or a volume less than 100mm3 was not predictive of cancer and maybe 
considered the most appropriate methodology for any future lung cancer screening 
programme. 
 
Reporting of false positives has varied in the literature. In NLST, any finding of a 
nodule ≥4mm diameter was classed as a false positive whereas NELSON defined 
categories of nodules that merely required follow-up LDCT as intermediate. In the 
UKLS trial, this distinction has been further clarified according to the variable 
potential impact on the subject in a trial or the patient in a programme. A finding that 
turns out not to be cancer yet mandates referral to the lung cancer MDT will usually 
be associated with significant psychological distress, and additional more or less 
invasive investigations with, in some cases, definitive treatment. An individual with a 
false positive so defined is thus more likely to suffer harm than one defined in a 
different way; that is, those subjects who are recalled solely for further CT imaging to 
investigate the nature of a nodule. The latter situation has been termed “Interval 
Imaging Rate” and may, in screening programmes, merely mean continuing in the 
programme rather than referral to the MDT. Thus the definition of ‘False Positive’ 
and ‘Interval Imaging Rates’ in the UKLS trial, encapsulates the concept of the level 
of harms to the trial participants. The UKLS false positive rate was 3.6% and the 
interval imaging rate was 23.2%, very similar to the false positive and intermediate 
finding rates in NELSON of 19% and 3.6% . In NLST, the false positive rate (at least 
4mm diameter nodule) was 24.2% of all CTs [17]. This difference is entirely due to 
the different definitions. [27] [18]. While the rate of interval imaging investigation 
might be acceptable, there is clearly room for better classification of the risk posed by 
nodules and for reduction of this rate. 
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7. Referral to MDT in Centre of Excellence   (Green) 	  
The NLST, NELSON and the UKLS all referred trial participants to the MDT for 
clinical workup.  There is no internationally agreed protocol for the work-up of CT 
detected nodules that meet criteria for referral for further investigation. Several 
guidelines are available for the management of lung cancer which apply to pulmonary 
nodules with a high chance of malignancy. The first step for a growing or larger 
nodule (>10mm or 500mm3 in NELSON and UKLS) is to do a PET-CT. In the 
recently published BTS guidelines on the investigation and management of 
pulmonary nodules, it is recommended that this is followed by a further risk 
assessment using the Herder model [24, 28]. Management is then guided by a 
combination of the risk of malignancy, fitness of the patient and most importantly, 
patient preference.  For low risk (<10%) further imaging follow-up is preferred, for 
intermediate risk (10-70%) biopsy to confirm the diagnosis is preferred and for high 
risk >70% resection or treatment may be offered as a first choice after a fully 
informed discussion. Other guidelines give a similar message although risk categories 
vary and there is no use of the Herder model (AUC >0.9 in validation studies) . Along 
with nodule management it is important to accurately assess fitness for treatment and 
treat comorbidities [29, 30].    
 
8.  Treatment of Lung Cancer (Green) 
 
Screen-detected lung cancer is mostly early stage and therefore amenable to curative 
treatment. The accepted gold standard is surgical resection. Current guidelines 
recommend lobectomy as the preferred operation, although sub-lobar resection may 
be performed if lung tissue needs to be spared owing to poor baseline lug function. 
Lobectomy has been shown to be superior to sub-lobar resection although the latter 
included both wedge resection and anatomical segmentectomy [31, 32] and the 
groups were dissimilar. There is currently some debate about whether anatomical 
segmentectomy is as good as lobectomy, especially for sub 2cm lesions [33, 34] .   
Localization of smaller pulmonary nodules can be achieved by a variety of 
preoperative techniques including radiologically guided injection of markers or 
placing of hook wires. No one technique has been shown to be superior so that the 
technique used will be dependent on local expertise and resources[24].  If surgery is 
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not possible due to patient fitness then radical radiotherapy is indicated, and because 
lesions are often small, stereotactic ablative radiotherapy (SABR) is preferred.  The 
latter has been shown, in one propensity matched study, to be equivalent to surgery  
[35]. Three RCTs of surgery vs. SABR have failed to recruit but a further one is 
currently underway in the UK (SABRTOOTH). 
 
9.   Mortality Data on LDCT Screening (Amber in Europe)  
 
There is only one trial to date with provides level one evidence for mortality data in 
lung cancer screening trials. The NLST showed a 20% gain in mortality in the CT 
arm compared to the chest X-ray arm of the trial.   However, the trial design chosen 
by the NLST does beg the question would this figure have been different if the trial 
had had a no-screen arm and thus potentially a higher mortality result might have 
been found. Three European trials, which were not adequately powered have reported 
on their mortality data, none of which should any significant increase in mortality in 
the CT screened arm [36-38] and thus can not be considered as level one evidence. 
This leaves Europe awaiting the outcome of the NELSON trial, to provide evidence 
on e way or the other on whether CT screening in Europe will have a significant 
mortality impact.  
 
Only the NELSON trial is powered at 80% to show a lung cancer mortality reduction 
of at least 25% 10 years after randomisation [39-41].  Three other European trials 
have published early mortality data. In two of the trials, the intervention group was 
offered annual low-dose CT screening [36, 42]. In the third, there were two active 
intervention groups, annual and biennial CT screening [43].  These three European 
trials, being underpowered and with suboptimal follow up periods, showed no 
significant reduction in lung cancer mortality. However, a meta-analysis including 
NLST yielded an overall mortality reduction of 19% (RR = 0.81, 95% CI 0.70-0.92), 
very similar to the result of the NLST alone [8] .  
 
Analysis of mortality data from NELSON may be possible in 2016 and there is the 
intention to pool results of the  UKLS trial [44].  The NLST is the dominant driver for 
implementation of LDCT screening in the USA but has not been accepted as the final 
decision in Europe; thus the reason why this section is scored “red”. 
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10.  Cost effectiveness of LDCT screening (Amber in Europe) 
 
In order to demonstrate that cancer screening would be cost effective by means of a 
randomised controlled trial requires the estimation of: the net costs of screening over 
detection via symptomatic presentation amongst trial subjects; net benefits, in terms 
of additional life expectancy on the part of screened subjects;  the ratio of net benefits 
to net costs incurred. However, this ratio of benefits to costs must be consistent with 
society’s attitude to the acceptable value for money in securing health gains. In the 
UK, the current convention for acceptability in the  public health care system is £20-
30,000 per quality-adjusted life year (QALY) gained[45]. 
 
The NLST has published an estimate of $81,000 per QALY as its mean ICER[46].  
This figure is about four times greater than the currently acceptable figure within the 
UK. However, as the authors have provided a great deal of data on how these figures 
were calculated, it has become clear that if the NLST had focused on the 40% of 
participants at highest risk, then the intervention becomes more cost effective, with 
the ICER halved. [46].	  
 
 
Pyenson and colleagues  [47] have modeled the cost and cost-effectiveness  of LDCT 
lung cancer screening of the Medicare population at high risk of lung cancer in the 
USA. Utilising the current Medicare costs from the 2012 Centers for Medicare & 
Medicaid Services (CMS) beneficiary files and these were forecasted to 2014, based 
on specific US projections.  They estimated that ~ 4.9 million high-risk Medicare 
beneficiaries would meet the USPSTF criteria for lung cancer screening in 2014 in 
individuals aged 55 to 80 years of age, with an estimated cost of $241 per person 
screened. The conclusion was that screening would be highly cost-effective, at 
<$19,000 per life-year saved for the Medicare beneficiaries and that an additional 
358,134 individuals with lung cancer (current and ex-smokers) would be alive in 
2014. It is of note that without screening, the Medicare patients with newly diagnosed 
lung cancer have an average life expectancy of approximately 3 years, much greater 
than the average seen globally.  
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Whynes [48] developed a simple, deterministic, model of a CT lung screening 
regimen, which could potentially be applicable to the UK.  The majority of the 
parameters included in the model had already been established in non-trial settings. 
The component costs of the modelling were derived from UK government guidance 
and from published audits, whilst the values for test parameters were derived from 
clinical studies. The expected health gains as a result of screening were calculated by 
combining published survival data for screened and unscreened cohorts with data 
from Life Tables. In order to estimate the most probable costs, conservative estimates 
were used, which would result in making screening appear less, rather than more, cost 
effective. This modelling provided an indication of the cost effectiveness of lung 
cancer screening in the UK. The incremental cost effectiveness ratio of a single screen 
amongst a high-risk male population was calculated to be around £14,000 per quality-
adjusted life year gained.  
 
The cost effectiveness of screening is a function of disease prevalence.  With a higher 
prevalence in the target population, more cases will be detected and more health gains 
will accrue for the same cost of screening [49].  A lung cancer screening programme 
which utilises a stringent risk prediction criterion for selection of the population will 
record a greater number of significant findings per person screened, and a lower 
ICER, than one with less strict risk prediction criteria.  Thus the value of assessing the 
correct risk prediction programme for the population under investigation is extremely 




11.  Frequency of Screening (Amber) 
 
The USPSTF has advocated that screening should be undertaken annually from 55 
years of age to 80 years of age in a pre-specified group of individuals as indicated 
earlier in the review.  However we do now have an opportunity to consider if this is 
appropriate taking into consideration the potential psychosocial harms, long term 
accumulation of radiation exposure and cost.  This concept has been modeled by 
Duffy et al [50] and clearly there are pros and cons in taking a less frequent approach 
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ie, biennial screening. To date the evidence base for low-dose CT screening for lung 
cancer pertains almost entirely to annual screening. Duffy and colleagues used the 
currently published data on lung cancer screening data from NLST and UKLS and 
natural history parameters to estimate the likely effects of annual and biennial 
screening programmes in different risk populations, in terms of deaths prevented as 
well as the human costs and included screening episodes, further investigation rates 
and overdiagnosis. 
 
The annual screening modelling with the UKLS eligibility criteria was estimated to 
result in 956 lung cancer deaths prevented and 457 over-diagnosed cancers from 
330,000 screening episodes. However, the biennial screening modelling would result 
in 802 lung cancer deaths prevented and 383 over-diagnosed cancers for 180,000 
screening episodes.  These predictions do suggest that the intervention effect could 
justify the human costs.  
 
The NELSON authors calculated the probabilities of developing lung cancer over a 
two year period, stratified by nodule characteristics. They reported that the 2-year 
lung cancer probability for all included participants was 1·3%, whilst participants 
without any pulmonary nodule in rounds one and two had a lung cancer probability of 
0·4%. In all participants with CT-detected nodules, lung cancer probability was 2.5%, 
but participants’ probabilities were dependent on nodule volume, diameter and 
volume doubling time. 
 
It is of note that more than half of the participants in the NELSON trial, no pulmonary 
nodules were detected. Their 2-year probability of developing lung cancer was 0·4%, 
which suggests that a screening interval of at least 2 years might be safe to apply in 
these individuals. 
 
Thus there is a potential benefit in considering biennial screening after two years of 
negative scans and justifies further empirical research, but can only be scored as 
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Final   recommendations – for planning and monitoring a future managing 
screening programme 
 
This review has focused on the evidence for implementing lung cancer screening at 
this time in Europe and thus dealt with the twelve major decision points in this 
process, however, any future decision will naturally have to include smoking 
cessation programmes and how they are incorporated, which has to be categorized as 
‘Amber’ at this time, as this will increase the cost effectiveness of the intervention 
 
There is considerable optimism around LDCT screening; however there will be 
difficult decisions around the overall cost.  
 
The evidence reviewed does point towards an annual screen, in the age group 60 to 74 
years, based on risk assessment and with a nodule cut-off in the region of 80-100mm3. 
However there is still uncertainty as to most effective method when engaging the hard 
to reach community, this has been categorized as “Red’. There is good evidence that 
once a 10mm diameter CT detected nodule is referred to a centre of excellence, there 
are currently high standard NICE guideline for both the work-up and treatment of 
these nodules. To date we do not have good mortality data in Europe, however this 
most likely will be available within the next 12 months from NELSON and in the UK 
we should then also have the benefit of the pooled NELSON and UKLS data.  In a 
similar time frame we should also have a better indication of the cost effectiveness of 
lung cancer screening in Europe, however both mortality data and cost effectiveness 
are still categorised in this review as ‘Amber’. Finally the decision to undertake 
yearly screening from 60 to 75 years of age after two negative scans will have to be 
further validated and thus has been categorised as ‘Amber’. 
 
Implementation, we believe, should be via a phased approach and further delay will 
mean lives lost.  
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